**Technology Advisory Committee A Interests Register**

**ID3742 Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer**

**Publication Date: 31/10/2024**

| Name | Role with NICE | Type of interest | Description of interest | Interest  declared | Interest  ceased | Comments |
| --- | --- | --- | --- | --- | --- | --- |
| Becky Pennington | Committee A Member | Direct – Financial Interests | Becky received consultancy fees from Roche for methods work, not related to trastuzumab or gastric cancer. | 19/10/2023 | N/A | It was agreed that Becky’s declaration would not prevent her from being part of the committee. |
| Hugo Pedder | Committee A Member | Direct - Financial Interests | Hugo expects to receive financial payment from Baxter Healthcare within the next 6 months for work on a treatment and indication unrelated to this. | 24/10/2023 | N/A | It was agreed that Hugo's declaration would not prevent him from providing from being part of the committee. |
| James Fotheringham | Committee A Member | Indirect - Financial Interests | Baxter Healthcare - James performed a scoping review on the evidence supporting remote monitoring of interventions for chronic diseases in the home setting. Paid to his employer. | 17/10/2023 | N/A | It was agreed that James's declaration would not prevent him from being part of the committee. |